Imvax (imvax.com): no confident changes recorded yet; website history since December 2013. Homepage last checked 6 November 2026.
First recorded website
Observed 2 May 2020
Our earliest capture with readable facts. This is our first observation, not when the company introduced these things. These website claims are not independently verified.
How it described itself
TRANSFORMING CANCER OUTCOMES ™
Imvax™ is a clinical-stage biotechnology company focused on the development of novel patient-specific vaccines and immunotherapy strategies for the treatment of malignant gliomas and other cancers wit
All facts above belong to this capture. Unlisted fields mean we have no readable observation, not that they were absent.
Recorded changes
Newest observations first. Each interval bounds when the website changed; it is not an exact event date.
No changes recorded yet. Missing observations do not mean the company has not changed.
How it describes itself
Similar headlines are grouped together. The quote shown is from the last capture in each group, not necessarily the exact wording throughout that period.
January 2022 – November 2026 · 7 captures · latest observed messagingTurning the complexity of a solid tumor against itself
Imvax is a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies.
18 January 2022 · Turning the complexity of solid tumors against themarchived page
3 July 2022 · Turning the complexity of solid tumors against themarchived page
7 September 2023 · Turning the complexity of a solid tumor against itselfarchived page
2 July 2024 · Turning the complexity of a solid tumor against itselfarchived page
9 July 2025 · Turning the complexity of a solid tumor against itselfarchived page
29 September 2026 · Turning the complexity of a solid tumor against itselfarchived page
6 November 2026 · Turning the complexity of a solid tumor against itselfcurrent websiteHistorical capture not publicly available
Seen May 2020 · 1 captureTRANSFORMING CANCER OUTCOMES ™
Imvax™ is a clinical-stage biotechnology company focused on the development of novel patient-specific vaccines and immunotherapy strategies for the treatment of malignant gliomas and other cancers wit